NASDAQ:DSGN - Design Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.33
  • Forecasted Upside: 122.92 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$15.85
▲ +0.74 (4.90%)

This chart shows the closing price for DSGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Design Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DSGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DSGN

Analyst Price Target is $35.33
▲ +122.92% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Design Therapeutics in the last 3 months. The average price target is $35.33, with a high forecast of $42.00 and a low forecast of $28.00. The average price target represents a 122.92% upside from the last price of $15.85.

This chart shows the closing price for DSGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Design Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2021SVB LeerinkInitiated CoverageOutperform$36.00High
4/20/2021The Goldman Sachs GroupInitiated CoverageNeutral$28.00High
4/20/2021Piper SandlerInitiated CoverageOverweight$42.00High
(Data available from 1/18/2017 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/19/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/18/2022

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Design Therapeutics logo
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.
Read More

Today's Range

Now: $15.85
Low: $14.45
High: $16.26

50 Day Range

MA: $18.36
Low: $15.11
High: $21.41

52 Week Range

Now: $15.85
Low: $12.52
High: $50.50

Volume

81,911 shs

Average Volume

80,350 shs

Market Capitalization

$882.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Design Therapeutics?

The following equities research analysts have issued stock ratings on Design Therapeutics in the last twelve months: Piper Sandler, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for DSGN.

What is the current price target for Design Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Design Therapeutics in the last year. Their average twelve-month price target is $35.33, suggesting a possible upside of 122.9%. Piper Sandler has the highest price target set, predicting DSGN will reach $42.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $28.00 for Design Therapeutics in the next year.
View the latest price targets for DSGN.

What is the current consensus analyst rating for Design Therapeutics?

Design Therapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DSGN will outperform the market and that investors should add to their positions of Design Therapeutics.
View the latest ratings for DSGN.

How do I contact Design Therapeutics' investor relations team?

Design Therapeutics' physical mailing address is 6005 HIDDEN VALLEY ROAD SUITE 110, CARLSBAD CA, 92011. The company's listed phone number is 858-293-4900 and its investor relations email address is [email protected] The official website for Design Therapeutics is www.designtx.com.